Cowen set a $42.00 target price on Boston Scientific (NYSE:BSX) in a research note issued to investors on Monday morning, The Fly reports. The firm currently has a buy rating on the medical equipment provider’s stock.

BSX has been the subject of several other research reports. Raymond James lifted their target price on shares of Boston Scientific from $40.00 to $41.00 and gave the stock a strong-buy rating in a research note on Tuesday, September 4th. Piper Jaffray Companies lifted their target price on shares of Boston Scientific to $38.00 and gave the stock an overweight rating in a research note on Thursday, July 26th. Morgan Stanley lifted their target price on shares of Boston Scientific from $33.00 to $38.00 and gave the stock an overweight rating in a research note on Thursday, July 26th. Jefferies Financial Group upgraded shares of Boston Scientific from a hold rating to a buy rating and lifted their target price for the stock from $34.00 to $42.00 in a research note on Tuesday, September 4th. Finally, Royal Bank of Canada lifted their target price on shares of Boston Scientific to $36.00 and gave the stock a top pick rating in a research note on Monday, July 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $38.70.

BSX opened at $36.62 on Monday. The stock has a market capitalization of $50.53 billion, a PE ratio of 29.06, a price-to-earnings-growth ratio of 2.54 and a beta of 0.59. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.83 and a quick ratio of 0.60. Boston Scientific has a twelve month low of $24.54 and a twelve month high of $39.44.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 25th. The medical equipment provider reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.07. The firm had revenue of $2.49 billion during the quarter, compared to the consensus estimate of $2.47 billion. Boston Scientific had a net margin of 5.48% and a return on equity of 26.35%. The company’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company earned $0.32 earnings per share. On average, equities research analysts anticipate that Boston Scientific will post 1.39 EPS for the current fiscal year.

In related news, Chairman Michael F. Mahoney sold 116,666 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $35.88, for a total transaction of $4,185,976.08. Following the completion of the transaction, the chairman now owns 2,023,104 shares of the company’s stock, valued at $72,588,971.52. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP David A. Pierce sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $33.66, for a total transaction of $168,300.00. Following the transaction, the executive vice president now directly owns 29,201 shares of the company’s stock, valued at approximately $982,905.66. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 295,834 shares of company stock valued at $11,038,468. 0.73% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the stock. Sei Investments Co. grew its stake in Boston Scientific by 7.8% in the 2nd quarter. Sei Investments Co. now owns 3,853,853 shares of the medical equipment provider’s stock worth $126,021,000 after buying an additional 278,777 shares in the last quarter. Waddell & Reed Financial Inc. purchased a new position in Boston Scientific in the 2nd quarter worth approximately $5,559,000. Cubist Systematic Strategies LLC grew its stake in Boston Scientific by 3.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 51,105 shares of the medical equipment provider’s stock worth $1,671,000 after buying an additional 1,547 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in Boston Scientific by 63.6% in the 2nd quarter. Nisa Investment Advisors LLC now owns 319,940 shares of the medical equipment provider’s stock worth $10,462,000 after buying an additional 124,350 shares in the last quarter. Finally, Public Employees Retirement System of Ohio grew its stake in Boston Scientific by 2.0% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 965,855 shares of the medical equipment provider’s stock worth $31,583,000 after buying an additional 19,383 shares in the last quarter. 91.02% of the stock is owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

See Also: Why Dividend Stocks May Be Right for You

The Fly

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.